|Year : 2015 | Volume
| Issue : 4 | Page : 123-130
Drug-resistant pathogens in community-acquired pneumonia
Ane Uranga1, Marcos I Restrepo2, James D Chalmers3, Francesco Blasi4, Stefano Aliberti5
1 Department of Pneumology, Hospital Galdakao-Usansolo, Galdakao, Vizcaya, Spain
2 Division of Pulmonary Diseases and Critical Care, South Texas Veterans Health Care System, University of Texas Health Science Center, San Antonio, Texas, USA
3 Tayside Respiratory Research Group, University of Dundee, Dundee, UK
4 Department of Pathophysiology and Transplantation, University of Milan, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
5 School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy
|Date of Web Publication||24-Dec-2015|
School of Medicine and Surgery, University of Milan Bicocca, Respiratory Unit, AO San Gerardo, Via Pergolesi 33, 20052, Monza
Source of Support: None, Conflict of Interest: None
An increasing prevalence of pneumonia caused by drug-resistant pathogens (DRPs) has been identifi ed. The 2005 American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) guidelines proposed the health care-associated pneumonia (HCAP) model in order to identify an increased risk of DRPs in patients coming from the community. These patients are known to have a worse prognosis, mostly due to poor functional status and treatment restrictions. New useful scores have been developed to help physicians in predicting DRPs. This manuscript is a review of currently published literature concerning the impact of CAP caused by DRPs and the different predictive models available.
Keywords: Community-acquired pneumonia (CAP), drug-resistant pathogens (DRPs), health care-associated pneumonia (HCAP), prediction models
|How to cite this article:|
Uranga A, Restrepo MI, Chalmers JD, Blasi F, Aliberti S. Drug-resistant pathogens in community-acquired pneumonia. Community Acquir Infect 2015;2:123-30
|How to cite this URL:|
Uranga A, Restrepo MI, Chalmers JD, Blasi F, Aliberti S. Drug-resistant pathogens in community-acquired pneumonia. Community Acquir Infect [serial online] 2015 [cited 2021 Sep 24];2:123-30. Available from: http://www.caijournal.com/text.asp?2015/2/4/123/172654
Pneumonia has been traditionally categorized as either community- or hospital-acquired, being caused by different organisms and characterized by different clinical outcomes. Community-acquired pneumonia (CAP) is predominantly caused by Streptococcus pneumoniae followed by Haemophilus influenzae, Staphylococcus aureus, viruses, and atypical bacterial pathogens. However, over the last 20 years new pathogens that were usually confined within the hospital setting have emerged in the community including methicillin-resistant S. aureus (MRSA), multidrug resistant Pseudomonas aeruginosa, or extended spectrum B-lactamase-producing Enterobacteriaceae. The present paper aims at reviewing the clinical and epidemiological impact of CAP caused by drug-resistant pathogens (DRPs) and available tools supporting physicians in predicting it.
| Introduction|| |
Different explanations for an increased prevalence of pneumonia caused by DRPs in the community could be identified. 1) During the past decades, health care systems in high-income countries underwent major changes. Along with the improvement of health care technologies, home health care, outpatient hemodialysis centers, nursing homes (NHs), and other long-term facilities became more widespread in the community. These changes led to a dynamic process with patients and physicians going in and out of health care facilities around the community and thus, DRPs. 2) The excessive and inappropriate use of antibiotics has been recognized as one of the major problems in Western countries. Antibiotic selection pressure is thought to be an important mechanism of selection for antibiotic resistance by reducing susceptible bacterial strains and shifting the competitive balance in favor of existing resistant strains. 3) The impact of an aging population has become a major issue of concern. Due to the growing elderly population, the use of antibiotics has notably increased with a higher number of patients being admitted to hospitals. Furthermore, these patients are regularly in contact with health care systems dealing with an increasing number of infections due to traditionally hospital-related pathogens. In the early 2000, the above demographic and sociocultural changes led to the introduction of the new concept of “health care-associated infection.” Friedman and coworkers first developed the new classification of “health care-associated bloodstream infections,” drawing the conclusion that these were similar to hospital-acquired infections in terms of frequency of various comorbid conditions, source of infection, pathogens and their susceptibility patterns, and mortality. In 2005, guidelines published by the American Thoracic Society (ATS)/Infectious Disease Society of America (IDSA) developed the definition of health care-associated pneumonia (HCAP) as a novel clinical entity including patients with frequent health care contacts and with an increased risk of pneumonia caused by DRPs. The definition of HCAP included any patient who was hospitalized in an acute care hospital for 2 or more days within 90 days of the infection, resided in a NH or long-term care facility (LTCF), received recent intravenous antibiotic therapy, chemotherapy, or wound care within the past 30 days of the current infection, attended a hospital or hemodialysis clinic, or had a family member with DRPs. The idea of HCAP was strengthened by a retrospective, multicenter study conducted in the USA by Kollef et al. enrolling 4,543 patients with pneumonia and positive cultures. The authors suggested that patients with HCAP were different from those with other types of pneumonia including CAP but similar in etiology to those patients with hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). However, this study was heavily criticized for showing that S. aureus was the most common cause of CAP, and that resistant pathogens were very common in CAP. These results were controversial and are discussed in more detail in the sections below.
| Main Drivers for the Occurrence on Pneumonia Caused by Drug-Resistant Pathogens in the Community|| |
Several risk factors are currently considered to be associated with the risk for DRPs in patients with pneumonia coming from the community. First of all, the importance of the evaluation of local patterns of antibiotic resistance as well as the rate of DRPs that could vary not only from country to country but also among different areas within the same country should be highlighted., Among all the risk factors for DRPs that constitute the HCAP definition, “recent hospitalization” seems to be the most frequent., Although the guidelines suggest “90 days” as the time limit for this risk factor, recent literature advocates that patients may be at risk for DRPs for even a 1-year period prior admission. These patients are known to be at an increased risk of colonization of the upper respiratory tract due to an alteration of normal flora probably secondary to a more recent antibiotic exposition with broad-spectrum antimicrobials that lead to a selection pressure for resistance. Moreover, previous antibiotic use by itself has been postulated as a risk factor for colonization and infection.
NH and LTCF residences have been evaluated as risk factors for DRPs. Patients residing in NH/LTCF have an increased risk of death per se due to advanced age, a high number of comorbidities, and a poor functional status. Solh et al. evaluated 88 NH patients with severe pneumonia confirmed by culture and showed that both the previous use of antibiotics and poor functional status were risk factors for DRPs. In this study, S. aureus was the predominant isolated pathogen (31%) followed by enteric gram-negative bacilli (28%) and S. pneumoniae (25%). Nevertheless, other authors described similarities in pathogen distribution between NH pneumonia and CAP. Part of the explanation for this heterogeneity may be the differences in what is considered a NH or skilled nursing facility in different countries. Therefore, the characteristics and functional status of patients classified as “nursing home residents” from one country may be very different to patients from another country.
Patients undergoing chronic hemodialysis usually have increased risk for both DRPs colonization and infection due contact with chronic indwelling vascular catheters, frequent skin punctures, severe comorbidities, and treatment with broad-spectrum antimicrobial agents. One study conducted among patients attending an ambulatory hemodialysis unit reported that 28% of the patients were colonized with one or more DRPs. In 2006, several outpatient hemodialysis facilities from the USA reported that the most frequent pathogen was S. pneumoniae with a very low rate of Staphylococcus species (2.2%) even though an etiological confirmation was reached only in 18% of the cases. Little is known about the risk of patients receiving home infusion therapy or wound care with a lack of epidemiological studies evaluating these patients. Different authors estimate a prevalence with a variance of 2-18%., Finally, having a family member infected/colonized with DRPs has also been described as a risk factor for DRPs pneumonia. However, this recommendation made by international guidelines is not supported by strong evidence and it is based on an expert's opinions. Immunosuppression and/or immunosuppressive therapy have gained special interest as risk factors for DRPs during the past decades. Cecere et al. identified increasing age, use of immunosuppressant drugs, neutropenia, and cerebrovascular disease as predictors of increased mortality in patients with HCAP. However, several authors evaluated patients with immunosuppression and failed to demonstrate an association with infection due to DRPs., A possible explanation for this could be the presence of underlying conditions leading to a clearly different prognosis. The population of patients with immunosuppression is extremely heterogeneous including subjects infected with HIV, those receiving treatment for cancer or using immunosuppressive medications as well as patients with bone marrow or solid organ transplantations.
Among other risk factors not included in the original definition of HCAP that nevertheless could be associated with infections due to DRPs, we should finally acknowledge a poor functional status and multicomorbid condition. More specifically, chronic lung disease, diabetes, cerebrovascular disease, dementia, risk of aspiration, and use of gastric acid suppressive agents have been described among different studies.,, Health care-associated pneumonia versus community-acquired pneumonia: Who is the Ryder Cup winner?
Since the introduction in 2005 of the HCAP concept by the ATS/IDSA guidelines, many investigators have questioned its validity to identify pneumonia due to DRPs in patients coming from the community.,,,, The heterogeneous category of HCAP was firstly developed in the USA according to a retrospective multicenter study conducted among 4,543 patients with culture-positive pneumonia. As mentioned above, the prevalence of S. aureus in the HCAP, HAP, and VAP groups in this study was significantly higher than in patients with CAP. In addition, mortality risk was higher in HCAP when compared to CAP (19.8% vs. 10%; <0.0001) while S. aureus was the only pathogen associated with increased mortality in that population. However, the high incidence of resistant organisms even among patients coming from the community makes these results controversial. Micek et al., in a retrospective study in the USA enrolling 639 patients with culture-positive CAP and HCAP showed that not only was MRSA significantly higher among the HCAP population (26%) but also that S. pneumoniae, Haemophilus species, and methicillin-sensitive S. aureus (MSSA) were the predominant pathogens in CAP. The authors observed that patients with HCAP were more likely to receive inappropriate initial antimicrobial treatment and they drew the conclusion that consequently they were more likely to die during their hospitalizations.
Similarly, in both retrospective and prospective multicenter studies from Korea and Japan, a different spectrum of pathogens was described between HCAP and CAP patients. In this sense, a higher incidence of DRPs was reported among HCAP patients with Klebsiella pneumoniae followed by S. pneumoniae being the most frequent pathogen among HCAP patients in both the studies., More recently, another retrospective study from Korea described a higher incidence of DRPs in HCAP patients when compared to those with CAP. However, there were no differences between both the groups when compared to each pathogen alone while S. pneumoniae was the most frequent microorganism followed by S. aureus in both the groups. With regard to mortality, Jung et al. described a higher rate among HCAP patients, describing a relationship between excess of mortality and the presence of DRPs in patients with low or intermediate risk. Nevertheless, these data should be interpreted with caution due to the retrospective design and high prevalence of immunosuppressed patients. Shindo et al. stated that HCAP patients had more severe diseases, higher initial inappropriate antimicrobial treatment, and higher mortality when compared to CAP patients. Despite having more severe diseases, the rate of mechanical ventilation was similar in both groups, which leads to the idea that treatment restrictions could explain mortality differences between both the groups as suggested by Ewig et al. Contrary to previous data, several European studies addressed similarities in the etiological pattern between HCAP and CAP, with S. pneumoniae being the main causative microorganism and with a very low incidence of DRPs in both entities.,,, In addition, García-Vidal et al. showed that aspiration pneumonia was more frequent in HCAP patients, suggesting the same treatment for both CAP and HCAP patients after ruling out the presence of aspiration pneumonia. The conducted among the Community-Acquired Pneumonia Organization (CAPO) database highlights the idea of different microorganism patterns around the world while describing a predominance of Staphylococcus spp. in the USA (52%), with S pneumoniae being the most frequent pathogen in Europe (46%) and Latin America (25%).
Likewise, a study from UK showed that HCAP patients had high mortality rates as well as a high age and comorbid conditions. In addition, they appeared to have more risk factors for aspiration and interestingly, the authors collected a higher rate of treatment restrictions. After adjustment for all these factors, HCAP was not independently associated with a 30-day mortality. The rates of DRPs in this study were very low (<2% of cases). Moreover, in a prospective observational study conducted in Spain, HCAP patients showed a decreased autonomy in the Barthel score and a clear poorer prognosis with an increased short- and long-term mortality. The authors revealed a stronger association between HCAP and 1-year mortality rather than with the 30-day mortality, which emphasized the idea that a worse functional status could impact long-term outcomes.
Even though it seems there is an agreement about an increased mortality in HCAP patients, no significant difference in mortality was found between HCAP and CAP in a study conducted among critically ill patients in 34 intensive care units (ICUs) in Spain. These results may be partly due to the exclusion of immunosuppressed patients from the HCAP definition and the lower impact treatment restrictions have in these types of patients. Rello et al. also endorsed an excess of mortality among HCAP patients in a prospective cohort study with patients with bacteraemic pneumococcal pneumonia. However, the authors suggested that differences in mortality were probably due to differences in a patient's characteristics and indirect limitations of treatment support in this population.
Many studies failed to validate the HCAP concept outside the USA partly due to differences in methodologies with inclusion of immunocompromised patients and more severe patients as well as differences in antibiotic policies and health care systems. In this sense, Chalmers et al. conducted a meta-analysis of 24 studies that clearly weakened the concept of HCAP because of its poor ability to identify potentially resistant pathogens. The HCAP concept was only 70% accurate in identifying DRPs, with better accuracy for MRSA but poor accuracy for P. aeruginosa. In addition, the meta-analysis identified publication bias, suggesting that studies with a high frequency of DRPs were being preferentially published. The recommendation supported by the studies from the USA in targeting DRPs with broad-spectrum antibiotics could lead to overtreatment, resulting in increased cost, Clostridium difficile infection, drug toxicity, and antibiotic resistance. Still, there is a wide heterogeneity among different health care systems around the world with different managements concerning pneumonia in each country and a general approach becomes a crucial issue. Prevalence of DRPs across different countries is shown in [Figure 1], according to both retrospective and prospective studies published so far.,,,,,,,,,,,,,,.,, Drug-resistant pathogen forecast: How can we predict drug-resistant pathogen storm?
| Risk Factors for Drug-Resistant Pathogens in Patients With Pneumonia Coming from the Community|| |
Different data from very heterogeneous studies have weakened the HCAP concept, making it difficult to get a consensus. Due to the limitations of the HCAP concept, identifying DRPs remains a difficult challenge. In an attempt to deal with these difficulties, some investigators have developed risk scores to identify DRPs; see [Table 1].
|Figure 1: Worldwide revalence of drug-resistant pathogens in patients with pneumonia coming from the community|
Click here to view
In 2004, Solh et al. conducted an observational study among 88 NH severe patients admitted to the ICU. The authors developed a classification tree using functional status and antibiotic use within 180 days with a sensitivity of 100% [95% confidence interval (CI), 80.3-100%] and a specificity of 53.5% (95% CI, 41.3-65.5%). Specificity increased up to 69.4% (95% CI, 51.9-83.6%) when validated in a separate cohort with 47 patients over a 24-month period. Similarly, Brito et al. proposed an algorithm that divided patients into four groups based on the severity of illness (need of mechanical ventilation or ICU admission) and several risk factors previously published (immunosuppression, hospitalization within the past 3 months, antibiotic therapy within the past 6 months, and poor functional status). This decision tree has been recently validated in a multicenter Japanese study with 445 patients with CAP and HCAP. The authors observed that by using this algorithm only 7.1% of HCAP patients received inappropriate therapy, mostly those with ≥2 risk factors. However, inappropriate therapy was not associated with increased risk of 30-day mortality.
In 2008, Shorr et al. highlighted that HCAP criteria led to misclassification of one-third of the patients with current presence of DRPs. Moreover, the authors published the first prediction score derived in a retrospective cohort with 639 patients with pneumonia, out of whom 45.2% presented with DRPs. The score included recent hospitalization, NH residence, hemodialysis, and intensive care unit admission assigning 4, 3, 2, and 1 points, respectively, with an area under the receiver operating characteristic (ROC) curve of 0.74 (95% CI, 0.65-0.80). When the same group validated the score in a similar retrospective cohort with a high prevalence of DRPs, the area under receiver operating characteristic (AUROC) for HCAP was 0.62 (95% CI, 0.58-0.65) versus 0.71 (95% CI, 0.66-0.73%) for the risk score. According to the score, only 24.3% of the patients would receive unnecessary extended-spectrum antibiotics. Nevertheless, the generalizability of this model is limited due to the high prevalence of DRPs and high rate of severe patients with more than half of the patients being admitted to ICU; see [Table 1].
In an attempt to predict DRP causing pneumonia in a more heterogeneous cohort, Aliberti et al. derived a weighted, prospective score including NH or extended care facility, recent hospitalization, chronic renal failure as well as minor risk factors such as chronic obstructive pulmonary disease, cerebrovascular disease, diabetes mellitus, antimicrobial therapy in the preceding 90 days, immunosuppression, home wound care, and home infusion therapy including antibiotics. The variables were pointed from 0.5 points if minor risk factors were met to 5 points if chronic renal failure was met with an AUROC of 0.79 (95% CI, 0.71-0.87). Later on, the model was prospectively validated for the presence of DRPs pneumonia in Spanish and Scottish cohorts with an AUROC of 0.89 (95% CI, 0.70-0.83) and 0.77 (95% CI, 0.71-0.84), respectively. Both Aliberti and Shorr scores performed better than HCAP classification in predicting DRP pneumonia while Aliberti score showed a slightly better performance than Shorr's one without reaching statistical significance. In contrast to Shorr's study, the prevalence of DRPs was very low in this population.
Park et al., developed a predicting score among a population with 36% prevalence of DRP by assigning 5 points for nasogastric tube feeding, 3 points for hospitalization within previous 90 days, 2 points for intravenous antibiotics within previous 30 days, and 1 point each for residence in a NH or extended-care facility, chemotherapy or wound care within 30 days of diagnosed pneumonia, or undergoing chronic dialysis. The predictive accuracy of the new scoring system was significantly higher than that of the current HCAP criteria with an AUC of 0.71 (95% CI, 0.66-0.76) and 0.63 (95% CI, 0.58-0.69). Recently, Wang et al. showed that the addition of a few risk factors to the pneumonia severity index (PSI) score could slightly improve the accuracy to predict DRP pathogens. The authors suggested broad-spectrum antibiotics covering P. aeruginosa for PSI risk classes III and IV patients with bronchiectasis and tube feeding as well as additional antibiotics covering MRSA for PSI risk class V patients who received wound care within 1 month.
Another multicenter study from Japan described a prospective model assigning 1 point to each risk factor (hospitalization within the previous 90 days, antibiotics within the previous 90 days, immunosuppression, use of gastric acid-suppressive agents, tube feeding, and poor functional status). The sum of six risk factors showed an AUROC of 0.79 (95% CI, 0.74-0.84) in contrast to 0.71 (95% CI, 0.66-0.77) and 0.66 (95% CI, 0.61-0.71) of Shorr and Aliberti scores, respectively.
Schreiber et al. described another predicting score derived in a retrospective cohort of severe patients admitted to the ICU with respiratory failure requiring mechanical ventilation. The authors assigned 3 points to immunosuppression, 2 points to long-term care, and 1 point to prior antibiotic use with a moderately well performance. Madaras-Kelly et al. derived a retrospective model among HCAP patients by the inclusion of risk factors for MRSA colonization, long-term care, infusion therapy, cephalosporin use, diabetes, and severity with an AUROC of 0.71 (95% CI, 0.65-0.77). Still, the last three models proposed have not been validated.
Finally, Prina et al. proposed the acronym “PES” in order to identify the three most common pathogens that need a different treatment in CAP; P. aeruginosa, Enterobacteriaceae extended-spectrum β-lactamase-positive, and methicillin-resistant Staphylococcus aureus. In an observational prospective study evaluating only immunocompetent patients with CAP, they identified 6% of the patients with pneumonia caused by PES. Furthermore, the presence of PES pathogens seems to be independently associated with an increased risk of 30-day mortality. As noted above, it is difficult to establish even in prospective studies if this increase in mortality is directly due to the pathogens or the marked differences in the demographics of patients' susceptibility to DRPs.
How to identify a pneumonia caused by P. aeruginosa in the community?
Few studies have been designed to help physicians in predicting pneumonia due to a single DRP in patients coming from the community including P. aeruginosa and MRSA. Despite being infrequent, CAP due to P. aeruginosa has been associated with more severe illness and worse outcomes., In this sense, Oriol et al., developed a retrospective study among 150 hospitals from the USA focused on identifying risk factors for P. aeruginosa. The authors described that only one-third of the current risk factors could identify P. aeruginosa. Additionally, they found that not receiving empirical antibiotics against it was associated with an increased 30-day mortality, especially among patients with cerebrovascular disease or dementia but without other specific risk factors.
How to identify a pneumonia caused by methicillin-resistant S. aureus in the community?
Patients with MRSA pneumonia present with more severe illness and higher morbidity and mortality rates compared to pneumonia caused by other pathogens. A study conducted in the USA from 2008 through 2012 described an increasing incidence of health care-related MRSA pneumonia. However, identifying pneumonia caused by MRSA by the current definition of HCAP seems to be difficult in clinical practice.
Shorr et al., developed a retrospective multicenter study enrolling 5,975 patients with pneumonia among 62 hospitals from the USA. The authors tried to identify the presence of MRSA by developing a weighted score based on age, prior health care exposure, severity of illness, and various comorbid conditions. Each variable was assigned 1 point except for recent hospitalization and severity of illness that were assigned two points. The score was able to identify patients at low risk for MRSA in whom unnecessary antibiotic treatments could be avoided. In this study, HCAP definition was an independent predictor of MRSA but not as robust as some of its components; thus, it was finally excluded from the final model. Furthermore, most of the variables in the score for MRSA were similar to those in the score for DRPs in general, highlighting the need for a more comprehensive evaluation of risk factors for MRSA. Minejima et al. compared retrospectively 134 MRSA pneumonia patients versus non-MRSA pneumonia and showed that most MRSA pneumonias (66%) were treated empirically with MRSA therapy. However, better outcomes were not observed among those patients.
More recently, Teshome et al. conducted a retrospective study enrolling 80,330 patients hospitalized in the Veterans Health Administration (VA) in order to assess the effect of initial MRSA therapy on the 30-day mortality in the three risk groups of the above score. The authors observed a lower mortality rate among high-risk patients with an initial MRSA therapy. Moreover, five patients should be treated with initial MRSA therapy in order to save one life in the high-risk group. In contrast, initial MRSA therapy was not beneficial in low- or medium-risk groups. However, the score proposed by Shorr et al. could not be completely assessed in this study due to the lack of patients <65 years as well as the higher prevalence of males in the VA system.
All the above scores have demonstrated a better accuracy than HCAP. However, most scores were focused on predicting DRPs in general but none could distinguish between different etiological microorganisms probably due to an overlap in this path of lights and shadows. At the moment, a Global Initiative for MRSA Pneumonia (GLIMP) study is being developed. This is the first international study to assess risk factors for MRSA in adult patients admitted to the hospital with either CAP or HCAP worldwide and promising results are expected in the near future. Therefore, further studies should be developed focused on identifying specific risk factors for specific drug-resistant microorganisms in order to help clinicians with decision-making while avoiding unnecessary broad-spectrum antibiotic treatments.
|Table 1: Clinical prediction models for drug-resistant pathogens (DRPs) in community-acquired pneumonia (CAP)|
Click here to view
During the last few decades, an increased prevalence of pneumonia caused by DRPs has been described due to dynamic changes of different health care systems, antibiotic selection pressure, and an aging population. The HCAP definition has shown several limitations for identifying DRPs in patients with CAP, especially outside the USA. However, different useful prediction scores have been recently developed. Further research is needed in order to support physicians in distinguishing between different DRPs causing pneumonia.
Financial support and sponsorship
Dr. Restrepo is partially supported by award number K23HL096054 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health or the Department of Veterans Affairs.
Conflicts of interest
There are no conflicts of interest.
| Conclusions|| |
| References|| |
Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al
.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-72.
American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
World Health Organization. WHO Global Strategy for Containment of Antimicrobial Resistance. Switzerland: World Health Organization; 2001. p. 1-99.
Summary of the lates data on antibiotic consumption in the European Union. Stockholm: European Centre for Disease Prevention and Control; 2014. p. 1-12.
Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al
. Health care — associated bloodstream infections in adults: A reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002;137:791-7.
Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: Results from a large US database of culture-positive pneumonia. Chest 2005;128:3854-62.
Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Shiraki A, et al
. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 2013;188:985-95.
Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: A single-center experience. Antimicrob Agents Chemother 2007;51:3568-73.
Venditti M, Falcone M, Corrao S, Licata G, Serra P; Study Group of the Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 2009;150:19-26.
DalBen MF, Basso M, Garcia CP, Costa SF, Toscano CM, Jarvis WR, et al
. Colonization pressure as a risk factor for colonization by multiresistant Acinetobacter spp and carbape- nem-resistant Pseudomonas aeruginosa in an inten-sive care unit. Clinics (Sao Paulo) 2013;68:1128-33.
Niederman MS. Gram-negative colonization of the respiratory tract: Pathogenesis and clinical consequences. Semin Respir Infect 1990;5:173-84.
Lim WS, Macfarlane JT. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. Eur Respir J 2001;18:362-8.
El-Solh AA, Pietrantoni C, Bhat A, Bhora M, Berbary E. Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. Clin Infect Dis 2004;39:474-80.
Calfee DP. Multidrug-resistant organisms in dialysis patients. Semin Dial 2013;26:447-56.
Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of pneumonia in hemodialysis patients: The USRDS waves 1, 3, and 4 study. Kidney Int 2006;70:1135-41.
Rello J, Lujan M, Gallego M, Valles J, Belmonte Y, Fontanals D, et al
.; PROCORNEU Study Group. Why mortality is increased in health-care-associated pneumonia: Lessons from pneumococcal bacteremic pneumonia. Chest 2010;137:1138-44.
Cecere LM, Rubenfeld GD, Park DR, Root RK, Goss CH. Long-term survival after hospitalization for community-acquired and healthcare-associated pneumonia. Respiration 2010;79:128-36.
Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med 2008;168:2205-10.
Aliberti S, Di Pasquale M, Zanaboni AM, Cosentini R, Brambilla AM, Seghezzi S, et al
. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia. Clin Infect Dis 2012;54:470-8.
Attridge RT, Frei CR. Health care-associated pneumonia: An evidence-based review. Am J Med 2011;124:689-97.
Murri R, De Pascale G. The challenge of identifying resistant-organism pneumonia in the emergency department: Still navigating on the erie canal? Clin Infect Dis 2012;54:199-201.
Shorr AF, Zilberberg MD. Role for risk-scoring tools in identifying resistant pathogens in pneumonia: Reassessing the value of healthcare-associated pneumonia as a concept. Curr Opin Pulm Med 2015;21:232-8.
Ewig S, Welte T, Torres A. Is healthcare-associated pneumonia a distinct entity needing specific therapy? Curr Opin Infect Dis 2012;25:166-75.
Lee B, Boucher HW. Targeting antimicrobial-resistant bacterial respiratory tract pathogens: It is time to 'get smart'. Curr Opin Pulm Med 2015;21:293-303.
Jung JY, Park MS, Kim YS, Park BH, Kim SK, Chang J, et al
. Healthcare-associated pneumonia among hospitalized patients in a Korean tertiary hospital. BMC Infect Dis 2011;11:61.
Koh SJ, Lee JH. Clinical characteristics of nursing home-acquired pneumonia in elderly patients admitted to a Korean teaching hospital. Korean J Intern Med 2015;30:638-47.
Ewig S, Torres A. Healthcare-associated pneumonia: Meeting the yeti. Eur Respir J 2011;38:755-7.
Garcia-Vidal C, Viasus D, Roset A, Adamuz J, Verdaguer R, Dorca J, et al
. Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. Clin Microbiol Infect 2011;17:1659-65.
Carratala J, Mykietiuk A, Fernandez-Sabe N, Suarez C, Dorca J, Verdaguer R, et al
. Health care-associated pneumonia requiring hospital admission: Epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 2007;167:1393-9.
Chalmers JD, Taylor JK, Singanayagam A, Fleming GB, Akram AR, Mandal P, et al
. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: A UK cohort study. Clin Infect Dis 2011;53:107-13.
Ewig S, Klapdor B, Pletz MW, Rohde G, Schutte H, Schaberg T, et al
.; CAPNETZ study group. Nursing-home-acquired pneumonia in Germany: An 8-year prospective multicentre study. Thorax 2012;67:132-8.
Liapikou A, Polverino E, Cilloniz C, Peyrani P, Ramirez J, Menendez R, et al
.; Community-Acquired Pneumonia Organization (CAPO) Investigators. A worldwide perspective of nursing home-acquired pneumonia compared with community-acquired pneumonia. Respir Care 2014;59:1078-85.
Polverino E, Torres A, Menendez R, Cilloniz C, Valles JM, Capelastegui A, et al
.; HCAP Study investigators. Microbial aetiology of healthcare associated pneumonia in Spain: A prospective, multicentre, case-control study. Thorax 2013;68:1007-14.
Valles J, Martín-Loeches I, Torres A, Díaz E, Seijas I, López MJ, et al
. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: A Spanish cohort study. Intensive Care Med 2014;40:572-81.
Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: A systematic review and meta-analysis. Clin Infect Dis 2014;58:330-9.
Webb BJ, Dascomb K, Stenehjem E, Dean N. Predicting risk of drug-resistant organisms in pneumonia: Moving beyond the HCAP model. Respir Med 2015;109:1-10.
Brito V, Niederman MS. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis 2009;22:316-25.
Maruyama T, Fujisawa T, Okuno M, Toyoshima H, Tsutsui K, Maeda H, et al
. A new strategy for healthcare-associated pneumonia: A 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis 2013;57:1373-83.
Aliberti S, Cilloniz C, Chalmers JD, Zanaboni AM, Cosentini R, Tarsia P, et al
. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: A European perspective. Thorax 2013;68:997-9.
Park SC, Kang YA, Park BH, Kim EY, Park MS, Kim YS, et al
. Poor prediction of potentially drug-resistant pathogens using current criteria of health care-associated pneumonia. Respir Med 2012;106:1311-9.
Schreiber MP, Chan CM, Shorr AF. Resistant pathogens in nonnosocomial pneumonia and respiratory failure: Is it time to refine the definition of health-care-associated pneumonia? Chest 2010;137:1283-8.
Madaras-Kelly K, Remington RE, Fan VS, Sloan KL. Predicting antibiotic resistance to community-acquired pneumonia antibiotics in culture-positive patients with healthcare associated pneumonia. J Hosp Med 2012;7:195-202.
Shorr AF, Zilberberg MD, Reichley R, Kan J, Hoban A, Hoffman J, et al
. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 2012;54:193-8.
Wang PH, Wang HC, Cheng SL, Chang HT, Laio CH. Selection of empirical antibiotics for health care-associated pneumonia via integration of pneumonia severity index and risk factors of drug-resistant pathogens. J Formos Med Assoc 2015. [Epub ahead of print].
Prina E, Ranzani OT, Polverino E, Cillóniz C, Ferrer M, Fernandez L, et al
. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc 2015;12:153-60.
Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman M, et al
. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginos: Incidence, risk, and prognosis. Arch Intern Med 2002;162:1849-58.
Von Baum H, Welte T, Marre R, Suttorp N, Ewig S; CAPNETZ Stusy Group. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors. Eur Respir J 2010;35:598-605.
Sibila O, Laserna E, Maselli DJ, Fernandez JF, Mortensen EM, Anzueto A, et al
. Risk factors and antibiotic therapy in P. aeruginosa community-acquired pneumonia. Respirology 2015;20:660-6.
Minejima E, Lou M, Nieberg P, Wong-Beringer A. Patients presenting to the hospital with MRSA pneumonia: Differentiating characteristics and outcomes with empiric treatment. BMC Infect Dis 2014;14:252.
Lewis SS, Walker VJ, Lee MS, Chen L, Moehring RW, Cox CE, et al
. Epidemiology of methicillin-resistant Staphylococcus aureus pneumonia in community hospitals. Infect Control Hosp Epidemiol 2014;35:1452-7.
Shorr AF, Myers DE, Huang DB, Nathanson BH, Emons MF, Kollef MH. A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia. BMC Infect Dis 2013;13:268.
Teshome BF, Lee GC, Reveles KR, Attridge RT, Koeller J, Wang CP, et al
. Application of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatment. BMC Infect Dis 2015;15:380.
|This article has been cited by|
||Identification of hospitalized patients with community-acquired infection in whom treatment guidelines do not apply: a validated model
| ||Teresa Cardoso,Pedro Pereira Rodrigues,Cristina Nunes,Mónica Almeida,Joana Cancela,Fernando Rosa,Nuno Rocha-Pereira,Inês Ferreira,Filipa Seabra-Pereira,Prudência Vaz,Liliana Carneiro,Carina Andrade,Justin Davis,Ana Marçal,N Deborah Friedman |
| ||Journal of Antimicrobial Chemotherapy. 2019; |
|[Pubmed] | [DOI]|
||Integrated safety summary of phase II and III studies comparing oral nemonoxacin and levofloxacin in community-acquired pneumonia
| ||Shih-Lung Cheng,Ren-Guang Wu,Yin-Ching Chuang,Wann-Cherng Perng,Shih-Ming Tsao,Yu-Ting Chang,Li-Wen Chang,Ming-Chu Hsu |
| ||Journal of Microbiology, Immunology and Infection. 2018; |
|[Pubmed] | [DOI]|
||Comparative efficacy and safety analysis of CSE-1034: An open labeled phase III study in community acquired pneumonia
| ||Manu Chaudhary,Shiekh G. Ayub,Mohd A. Mir |
| ||Journal of Infection and Public Health. 2018; 11(5): 691 |
|[Pubmed] | [DOI]|